Durability of Antibody Responses to SARS-CoV-2 Infection and Its Relationship to Disease Severity Assessed Using a Commercially Available Assay

Alanoud Alshami; Rabab Al Attas; Hadeel Anan; Aroub Al Maghrabi; Salim Ghandorah; Amani Mohammed; Abdulbary Alhalimi; Jumana Al-Jishi; Hadi Alqahtani

doi:10.3389/fmicb.2021.770727

Durability of Antibody Responses to SARS-CoV-2 Infection and Its Relationship to Disease Severity Assessed Using a Commercially Available Assay

Front Microbiol. 2021 Dec 3:12:770727. doi: 10.3389/fmicb.2021.770727. eCollection 2021.

Authors

Alanoud Alshami¹, Rabab Al Attas², Hadeel Anan¹, Aroub Al Maghrabi³, Salim Ghandorah², Amani Mohammed², Abdulbary Alhalimi⁴, Jumana Al-Jishi⁵, Hadi Alqahtani⁶

Affiliations

¹ Department of Epidemiology and Biostatistics, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia.
² Division of Immunology, Department of Pathology and Laboratory Medicine, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia.
³ Alfaisal University, Riyadh, Saudi Arabia.
⁴ King Faisal University, Al-Ahsa, Saudi Arabia.
⁵ Division of Infectious Disease, Department of Internal Medicine, Qatif Central Hospital, Qatif, Saudi Arabia.
⁶ Division of Infectious Disease, Department of Pediatrics, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia.

Abstract

Background: Assessing the humoral immune response to SARS-CoV-2 is crucial for inferring protective immunity from reinfection and for assessing vaccine efficacy. Data regarding the durability and sustainability of SARS-CoV-2 antibodies are conflicting. In this study, we aimed to determine the seroconversion rate of SARS-CoV-2 infection in a cohort of reverse-transcriptase polymerase chain reaction (RT-PCR)-confirmed SARS-CoV-2 infections and the antibody dynamics, durability, and the correlation of antibody titers with disease severity using the commercially available SARS-CoV-2 anti-spike (S1/S2) protein. Methods: A total of 342 subjects with PCR-confirmed COVID-19 were enrolled. A total of 395 samples were collected at different time points (0-204) after the onset of symptoms or from the day of positive PCR in asymptomatic patients. Demographics, clinical presentation and the date of PCR were collected. All samples were tested using the automated commercial chemiluminescent system (DiaSorin SARS-CoV-2 S1/S2 IgG) on the LIAISONXL^® platform (LIAISON). Results: The seroconversion rate for samples collected 14 days after the onset of infection was much higher than that for samples collected before 14 days (79.4% vs. 39.4%). The rate of seroconversion in symptomatic participants (62.1%) was similar to that of asymptomatic participants (56.1%) (p = 0.496). The IgG titer distribution was also similar across both groups (p = 0.142), with a median IgG level of 27.86 AU/ml (3.8-85.5) and 15 AU/ml (3.8-58.85) in symptomatic and asymptomatic participants, respectively. However, IgG titers were significantly higher in ICU patients, with a median of 104 AU/ml (3.8-179) compared to 34 AU/ml (3.8-70) in the non-ICU participants (p < 0.0001). Furthermore, the median time to seroconversion occurred significantly faster in ICU patients than in non-ICU participants (19 versus 47 days) (P < 0.0001). IgG titers were also higher in subjects ≥50 years compared to those <50 years (p < 0.009), male compared to female (p < 0.054) and non-Saudi compared to Saudi (p < 0.003). Approximately 74% of all samples tested beyond 120 days were positive. Conclusion: Antibodies can persist in circulation for longer than 4 months after COVID-19 infection. The majority of patients with COVID-19 mounted humoral immune responses to SARS-CoV-2 infection that strongly correlated with disease severity, older age and male gender. However, the population of individuals who tested negative should be further evaluated.

Keywords: SARS-CoV-2; antibody; commercial assay; disease severity; durability; immune response.